R&D prices have been up $3 million, primarily pushed by investments in JRNY. In fiscal yr This autumn, promoting was $14 million versus $12 million final yr. And JRNY opex was $5 million versus $4 million final yr. Adjusted working loss was $21 million, and adjusted working margins have been detrimental 18%, in keeping with our steering.
And lastly, adjusted EBITDA loss from persevering with ops was $17 million or detrimental 14%. On slide 18, we included a waterfall that describes the year-over-year change in working margins. The drivers of the year-over-year decline are elevated product prices, logistics and discounting, greater ranges of investments in JRNY and incremental promoting. Turning now to the steadiness sheet as of March 31.
Comments
0 comments